Logos Capital

Boundless Bio, Inc., biopharma company, develops therapies and medicines for the treatment of cancers. It offers therapeutics based on extrachromosomal DNA (ecDNA) one of the drivers of the aggressive cancers, such as cancers characterized by high copy number amplification of oncogenes. The company was formerly known as Pretzel Therapeutics, Inc. Boundless Bio, Inc. was founded in 2018 and is based in LA Jolla, California.

Parse Biosciences, based in Seattle, Washington, focuses on single-cell analysis and was incorporated in 2018. The company is dedicated to developing innovative technologies that enhance the understanding of cellular diversity and function at the single-cell level. By leveraging advanced methodologies, Parse Biosciences aims to provide researchers with powerful tools for exploring complex biological systems, ultimately advancing the fields of genomics and biomedical research.

Enliven Therapeutics is a clinical-stage precision oncology company dedicated to the discovery and development of innovative small molecule therapies aimed at enhancing patient outcomes. The company focuses on addressing critical challenges in cancer treatment, such as tolerability, combinability, resistance, and disease progression, particularly in the context of brain metastases. Enliven's lead product candidates include ELVN-001, a selective small molecule kinase inhibitor targeting the BCR-ABL gene fusion associated with chronic myeloid leukemia, and ELVN-002, an irreversible HER2 inhibitor designed to penetrate the central nervous system and target both wild type HER2 and related variants. Through its advanced discovery process, Enliven Therapeutics aims to create first-in-class therapies that improve the quality of life for patients facing cancer.

Odyssey Therapeutics is a biotechnology company pioneering the efficient development of next-generation immunomodulators and oncology medicines. Odyssey is making a transformational impact on the field of drug discovery and is accelerating the path to clinical development to drive the creation of more effective precision medicines.

Alpine Immune Sciences, Inc. is a clinical-stage biopharmaceutical company based in Seattle, Washington, specializing in the discovery and development of protein-based immunotherapies aimed at treating cancer, autoimmune, and inflammatory disorders. The company's lead programs include ALPN-101, an antagonist targeting the inducible T cell costimulator and CD28 pathways for autoimmune and inflammatory diseases, and ALPN-202, which combines programmed cell death protein ligand 1 and cytotoxic T-lymphocyte associated protein 4 antagonism with PD-L1 dependent CD28 costimulation for cancer treatment. Additionally, Alpine has a collaboration with Kite Pharma, Inc. to develop immunotherapies that target the immune synapse for cancer therapy. The company utilizes a proprietary platform to transform native immune system proteins into innovative, multi-targeted therapeutics.

Operator of a biopharmaceutical company intended to discover and develop next-generation medicines for neurodegenerative diseases. The company is focused on developing small-molecule activators of glucocerebrosidase and advanced programs targeting the innate immune system that can accelerate the progression of several neurological diseases, enabling healthcare professionals to transform the lives of patients with treatments for various ailments.

RareCyte, Inc. is a life sciences company based in Seattle, Washington, that specializes in the development of liquid and tissue biopsy analysis platforms aimed at the detection of rare cells. Founded in 2009, RareCyte focuses on providing innovative technologies for the Life Sciences research, drug development, and diagnostic markets. The company offers a range of products, including sample preparation systems, staining kits, and automated fluorescence microscopy instruments. Its AccuCyte system is particularly notable for enabling the unbiased discovery and isolation of circulating tumor cells and circulating endothelial cells from whole blood. RareCyte's technologies are designed to address complex challenges in cancer and cardiovascular disease research, facilitating advancements in precision medicine and non-invasive prenatal testing.

Asher Biotherapeutics, Inc. is a biotechnology company focused on developing immunotherapy drugs for cancer treatment. Founded in 2019 and headquartered in South San Francisco, California, the company aims to create innovative therapeutic solutions to improve patient outcomes in oncology. Asher Bio leverages advanced technologies and research to enhance the effectiveness of immune-based therapies, positioning itself as a key player in the evolving field of cancer treatment.

Element Biosciences, Inc. develops genetic analysis tools for the research and diagnostic markets. The company provides a disruptive DNA sequencing technology and a sequencing platform, such as surface chemistry, sequencing chemistry, detection, and data analysis. The company was incorporated in 2017 and is based in San Diego, California.

Boundless Bio, Inc., biopharma company, develops therapies and medicines for the treatment of cancers. It offers therapeutics based on extrachromosomal DNA (ecDNA) one of the drivers of the aggressive cancers, such as cancers characterized by high copy number amplification of oncogenes. The company was formerly known as Pretzel Therapeutics, Inc. Boundless Bio, Inc. was founded in 2018 and is based in LA Jolla, California.

Century Therapeutics, Inc. is a biotechnology company focused on developing induced pluripotent stem cell (iPSC)-based therapies for cancer treatment. Founded in 2018 and headquartered in Philadelphia, Pennsylvania, the company aims to create allogeneic living drugs that specifically target both hematologic and solid tumors. By utilizing iPSCs, Century Therapeutics can engineer immune effector cells through multiple rounds of cellular modification, producing master cell banks that can be expanded and differentiated for therapeutic use. Their innovative approach incorporates advanced technologies such as CRISPR-mediated gene editing and proprietary chimeric antigen receptors, along with Allo-Evasion technology, which helps prevent rejection by the host immune system. These advancements position Century Therapeutics to enhance the effectiveness and accessibility of cancer treatments.

Vividion Therapeutics, Inc. is a biotechnology company based in San Diego, California, focused on developing therapeutics to address significant unmet medical needs. The company utilizes a novel platform for proteome-wide small molecule drug discovery, which combines proteomic techniques and synthetic chemistry to enhance drug selectivity and broaden the range of druggable proteins. Originating from research at The Scripps Research Institute, Vividion's technology enables the creation of detailed drug interaction maps, facilitating simultaneous target engagement and comprehensive selectivity profiling. By advancing its innovative synthetic and proteomic chemistry approaches, Vividion aims to deliver transformative treatments for patients with serious illnesses.

Shoreline Biosciences, Inc. is a biotechnology company based in La Jolla, California, founded in 2020. The company specializes in developing cell-based immunotherapies aimed at treating seriously ill patients. Shoreline utilizes a proprietary technology platform that focuses on induced pluripotent stem cell (iPSC) differentiation and the genetic programming of the IL-15/CISH pathway. This approach enhances the metabolic fitness and persistence of engineered natural killer (NK) cells, thereby improving their anti-cancer activity. In addition to NK cells, Shoreline is also advancing the development of iPSC-derived macrophages for oncology and disease-modifying therapies. The company's innovative solutions aim to provide healthcare professionals with effective and cost-efficient treatment options for patients facing serious health challenges.

Visen Pharmaceuticals is a biotechnology company dedicated to the development and commercialization of innovative endocrine drugs. The company aims to address significant unmet medical needs for patients in Greater China, focusing specifically on endocrine treatment solutions. By leveraging its expertise in biotechnology, Visen Pharmaceuticals seeks to improve patient outcomes through the creation of effective therapies in the field of endocrinology.

Scorpion Therapeutics, Inc. is a biotechnology company focused on developing next-generation precision oncology technologies aimed at improving cancer treatment. Founded in 2020 and based in Boston, Massachusetts, the company specializes in creating precision oncology drugs that target known oncogenes, address currently undruggable cancer targets, and explore new therapeutic targets. By integrating advanced technologies in target discovery, medicinal chemistry, and translational medicine, Scorpion Therapeutics seeks to expand the reach of precision medicine to a broader patient population. The company's approach is designed to unlock novel small-molecule drugs that can overcome the limitations of existing therapies, thereby enhancing treatment options for cancer patients.

IconOVir Bio is a preclinical-stage biotechnology company pioneering the next generation of oncolytic virus therapy to improve the treatment of patients with cancer.

SomaLogic operates as a protein biomarker discovery and clinical diagnostics company. It offers SOMAmers (Slow-Offrate Modified Aptamers), which are modified nucleic acid-based protein-binding reagents that are specific for their cognate protein; and SOMAscan that provides protein detection and equipment. The company’s SOMAmer/SOMAscan technology enables to discover protein biomarker signatures; drug discovery and development; and clinical diagnostics. Its products have applications in the diagnostics of various diseases in oncology, neurology, cardiovascular and metabolic disease, and other diseases and conditions. SomaLogic was founded in 1999 and is headquartered in Boulder, Colorado.

Flame Biosciences, Inc. is a clinical-stage biotechnology company based in New York that specializes in the research, development, and commercialization of innovative therapies targeting cancer and inflammatory diseases. Established in 2017, the company is advancing its FL-101 therapy, designed to treat lung cancers associated with inflammation, and FL-201, aimed at alleviating chronic inflammation in patients. By leveraging the emerging field of inflammasome science, Flame Biosciences seeks to provide effective treatments that enhance the quality of life for individuals affected by serious health conditions.

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic used for the treatment of myelodysplastic syndromes and acute myeloid leukemia, as well as a range of solid tumor indications, including head and neck squamous cell and human epidermal growth factor receptor 2 positive gastric/gastroesophageal junction carcinoma. The company was founded in 2015 and is based in Burlingame, California.

Passage Bio is a genetic medicines company based in Philadelphia, Pennsylvania, specializing in the development of therapies for rare monogenic central nervous system (CNS) diseases. Founded in 2017, the company aims to create a portfolio of five AAV-delivered therapeutics, targeting conditions such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease. Passage Bio collaborates closely with the University of Pennsylvania, leveraging its Gene Therapy Program for preclinical work while managing clinical development, regulatory affairs, manufacturing, and commercialization of its product candidates. The company also engages with the Orphan Disease Center for natural history studies, key opinion leader involvement, and patient advocacy.